Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study
Academic Article
Publication Date:
2021
Short description:
Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study / Barbanti, P., Aurilia, C., Cevoli, S., Egeo, G., Fofi, L., Messina, R., Salerno, A., Torelli, P., Albanese, M., Carnevale, A., Bono, F., D'Amico, D., Filippi, M., Altamura, C., Vernieri, F.. - In: HEADACHE. - ISSN 0017-8748. - 6:(2021), pp. 1351-1363. [10.1111/head.14194]
abstract:
To evaluate the long-term effectiveness, safety, and tolerability of erenumab in a real-world migraine population, looking for putative predictors of responsiveness.
Iris type:
1.1 Articolo in rivista
Keywords:
allodynia; calcitonin gene-related peptide; erenumab; long-term treatment; migraine; sex
List of contributors:
Barbanti, Piero; Aurilia, Cinzia; Cevoli, Sabina; Egeo, Gabriella; Fofi, Luisa; Messina, Roberta; Salerno, Antonio; Torelli, Paola; Albanese, Maria; Carnevale, Antonio; Bono, Francesco; D'Amico, Domenico; Filippi, Massimo; Altamura, Claudia; Vernieri, Fabrizio
Published in: